

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra  
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family searching

NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts

NEWS 26 JUN 06 KOREPAT updated with 41,000 documents

NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

**NEWS HOURS** STN Operating Hours Plus Help Desk Availability  
**NEWS LOGIN** Welcome Banner and News Items  
**NEWS IPC8** For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:29:37 ON 15 JUN 2008

=> file caplus  
**COST IN U.S. DOLLARS**  
 ENTRY      SINCE FILE      TOTAL  
**FULL ESTIMATED COST**      0.42      0.42

FILE 'CPLUS' ENTERED AT 09:30:37 ON 15 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 13 Jun 2008 (20080613/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s (aurora A) and (protein or kinase)

4516 AURORA

498 AURORAS

4597 AURORA

(AURORA OR AURORAS)

22194104 A

646 AURORA A

(AURORA(W)A)

2165629 PROTEIN

1523198 PROTEINS

2527018 PROTEIN

(PROTEIN OR PROTEINS)

321847 KINASE

60926 KINASES

331793 KINASE

(KINASE OR KINASES)

L1 605 (AURORA A) AND (PROTEIN OR KINASE)

=> s L1 and 35C1

11 35C1

L2 2 L1 AND 35C1

=> d L2 bib abs 1-2

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:990980 CAPLUS

DN 140:40888

TI Monoclonal antibodies to Aurora A kinase and  
their use in the diagnosis and treatment of cancer

IN Prigent, Claude; Martin, Anne

PA Centre National De La Recherche Scientifique Cnrs, Fr.

SO Fr. Demande, 33 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2840905	A1	20031219	FR 2002-7212	20020612
FR 2840905	B1	20060707		
CA 2489214	A1	20031224	CA 2003-2489214	20030612
WO 2003106500	A1	20031224	WO 2003-FR1772	20030612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003255671	A1	20031231	AU 2003-255671	20030612
EP 1511771	A1	20050309	EP 2003-760023	20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006513135	T	20060420	JP 2004-513330	20030612
US 20070117163	A1	20070524	US 2005-517645	20050210
PRAI FR 2002-7212	A	20020612		
WO 2003-FR1772	W	20030612		

AB The present invention has as an aim a monoclonal antibody directed against kinase aurora-A of the mammals, its process of obtaining, as its uses within the framework of the diagnosis or the forecast of cancers, and in pharmaceutical compns. within the framework of the treatment of cancers. Monoclonal antibodies have been raised against the Aurora A kinase for use in the diagnosis, prognosis, and treatment of cancer. The monoclonal antibody 35C1 does not inhibit Aurora A kinase

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:958062 CAPLUS

DN 138:285769

TI Preparation and characterization of a human aurora-A kinase monoclonal antibody

AU Cremet, Jean Yves; Descamps, Simon; Verite, Frank; Martin, Ann; Prigent, Claude

CS Faculte de medecine, IFR 97 Genomique et Sante, CNRS - UMR 60611 Genetique et Developpement, Universite de Rennes 1, Rennes, 35043, Fr.

SO Molecular and Cellular Biochemistry (2003), 243(1&2), 123-131  
CODEN: MCBIB8; ISSN: 0300-8177

PB Kluwer Academic Publishers

DT Journal

LA English

AB We have developed monoclonal antibodies against the human aurora -A serine/threonine kinase. After immunization of a mouse, a fusion was performed to obtain hybridomas that were selected because they produced Ig pos. reacting against the protein used for immunization. We isolated one particular monoclonal that we named 35C1 using a series of selective assays. The first criteria of the screen for monoclonals was an Elisa (Enzyme Linked Immunosorbant Assay) assay performed in 96-well plates against the purified recombinant histidine-tagged aurora-A. The second was a pos.

Western blot against the same recombinant protein. The third criteria was a pos. western blot against an HeLa cell ext., the selected monoclonal should detect only one protein migrating at 46 kDa (kiloDalton) on SDS (Sodium Dodecyl Sulfate)-polyacrylamide gel electrophoresis. Finally, the monoclonal had to bind to duplicated centrosomes and spindle poles in human MCF7 cultured cells by indirect immunofluorescence. At this stage several monoclonals were still pos. We then increased the selectivity by searching for antibodies that were able to cross-react with the mouse aurora-A kinase both by western blot and indirect immunofluorescence. We selected and cloned the 35C1 hybridoma to produce the antibody. Further characterization of the 35C1 antibody revealed that it was able to immunoppt. the kinase, that it did not inhibit the aurora-A kinase activity and consequently could be used to measure the aurora-A kinase activity *in vivo* after immunopptn.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT